Equities

Novocure Ltd

Novocure Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.82
  • Today's Change-0.37 / -2.03%
  • Shares traded1.01m
  • 1 Year change+60.11%
  • Beta0.7100
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

  • Revenue in USD (TTM)577.74m
  • Net income in USD-149.78m
  • Incorporated2000
  • Employees1.45k
  • Location
    Novocure LtdNo. 4 The Forum, Grenville StreetSAINT HELIER JE2 4UFJerseyJEY
  • Phone+44 1 534756700
  • Websitehttps://www.novocure.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Inmode Ltd423.75m153.67m1.49bn581.0010.562.199.643.511.851.855.048.920.52391.5810.15729,339.1019.0031.3220.7735.6481.6484.4636.2639.659.91--0.000.008.3237.4922.5454.6513.10--
STAAR Surgical Co341.22m21.78m1.50bn1.06k69.433.5054.194.390.43810.43816.908.690.67632.033.15323,128.804.326.774.927.9078.7376.896.389.165.38--0.00020.0013.3721.07-46.1833.8551.95--
Myriad Genetics, Inc.823.60m-116.00m1.57bn2.70k--2.15--1.91-1.30-1.309.218.040.73859.916.84305,037.00-10.40---12.43--69.15---14.08--1.73-105.000.0506--11.03---135.09------
Evolent Health Inc2.46bn-104.23m1.76bn4.70k--1.68120.760.714-0.9129-0.912921.5510.660.953--6.14524,309.40-2.79-9.60-3.58-12.5915.9624.50-2.93-13.66---0.55950.3285--45.2625.65-660.71---6.18--
Rxsight Inc128.29m-30.69m1.84bn374.00--6.73--14.33-0.8194-0.81943.406.890.52121.996.32343,029.40-12.47---13.62--68.44---23.92--11.71--0.0005--81.77--27.19------
Patterson Companies, Inc.6.53bn168.41m1.86bn7.60k11.501.957.190.2841.831.8371.2210.802.275.8615.35859,640.705.841.1310.151.8121.0320.982.570.51570.67237.910.4474304.751.503.34-10.4218.102.170.00
AtriCure Inc447.57m-38.92m1.86bn1.20k--4.00--4.16-0.8322-0.83229.569.540.73651.638.41372,977.50-6.40-3.72-7.35-4.1074.7974.36-8.70-7.642.59-13.760.1194--20.8414.6434.49--46.56--
10X Genomics Inc629.74m-182.55m1.92bn1.26k--2.66--3.06-1.53-1.535.265.970.66772.406.72500,193.00-19.36-25.52-21.99-29.0566.6375.88-28.99-48.534.12--0.00--19.8133.43-53.67--49.15--
Integra Lifesciences Holdings Corp1.56bn-6.54m1.96bn3.95k--1.2915.371.25-0.0881-0.088120.2219.730.4011.595.99396,583.90-0.16773.33-0.20023.6859.2963.67-0.41827.990.72614.050.54280.00-1.030.9219-62.482.19-2.97--
Novocure Ltd577.74m-149.78m1.97bn1.45k--5.45--3.41-1.39-1.395.373.340.48793.598.74397,617.30-12.65-7.74-20.29-8.9576.4277.22-25.93-14.691.44--0.6446---5.3015.47-123.75--32.19--
Tandem Diabetes Care Inc854.35m-126.78m2.06bn2.40k--8.66--2.41-1.94-1.9413.083.620.90042.908.23355,979.60-13.36-10.08-17.47-12.2349.7951.77-14.84-11.592.32--0.5945---6.6832.39-135.33--76.81--
Premier Inc1.28bn147.17m2.22bn2.90k16.721.168.461.741.381.3711.6519.980.3562--2.99439,914.103.837.084.788.9567.2461.2910.7616.05----0.277127.320.76842.03-31.70-11.93-2.76--
Omnicell Inc1.06bn-17.69m2.25bn3.66k--1.8433.862.11-0.3917-0.391723.1726.590.47045.904.06291,563.30-0.78171.73-1.112.2541.4446.69-1.662.920.9529--0.31720.00-11.487.82-460.68--0.235--
Conmed Corp1.29bn131.74m2.31bn4.00k17.702.4811.361.804.234.2341.3830.210.5551.715.58322,029.005.680.89726.621.0255.6554.9510.231.651.065.220.5021139.1619.067.68179.9910.042.890.00
LeMaitre Vascular Inc213.03m41.32m2.37bn614.0057.867.1646.5211.131.821.829.4114.730.59921.117.59346,952.8011.629.0212.669.9368.3465.8319.4015.455.52----40.4119.6912.8845.895.9618.9315.51
Warby Parker Inc742.53m-32.56m2.46bn2.14k--7.32216.583.31-0.2731-0.27316.202.801.225.70818.21346,975.20-5.37---6.78--55.3257.49-4.39-14.532.06--0.00--11.9819.6742.75------
Data as of Nov 12 2024. Currency figures normalised to Novocure Ltd's reporting currency: US Dollar USD

Institutional shareholders

56.92%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Jun 202416.14m14.92%
Capital Research & Management Co. (International Investors)as of 30 Jun 202411.70m10.81%
The Vanguard Group, Inc.as of 30 Jun 202410.82m10.00%
BlackRock Fund Advisorsas of 30 Jun 20248.49m7.84%
Nordwand Advisors LLCas of 30 Sep 20243.03m2.80%
SSgA Funds Management, Inc.as of 30 Jun 20243.01m2.78%
Geode Capital Management LLCas of 30 Jun 20242.38m2.20%
Capital Research & Management Co. (World Investors)as of 30 Jun 20242.31m2.13%
T. Rowe Price Associates, Inc. (IM)as of 30 Jun 20242.02m1.87%
T. Rowe Price Investment Management, Inc.as of 30 Jun 20241.71m1.58%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.